Joel Beatty

Mar 10, 2026

On Mar 10, 2026, DNTH was given a Outperform rating by Joel Beatty, with a target price of 132. Despite the Buy call, shares fell from 77.86 to 77.86, challenging the optimistic stance.

Mar 06, 2026

CTNM received a Outperform rating from Joel Beatty on Mar 06, 2026, aiming for 20. The rating hasn’t played out as hoped, with the stock trading 6.34% below expectations.

Feb 20, 2026

On Feb 20, 2026, Joel Beatty published a Outperform outlook on PRAX, with a target of 433. Market action contradicted the Buy thesis, as shares slipped to 293.95.

Dec 30, 2025

Joel Beatty on Dec 30, 2025 assigned RARE a Outperform rating, with a price target of 72. The call has struggled to gain traction, with shares losing 6.32%.

Nov 18, 2025

On Nov 18, 2025, Joel Beatty reaffirmed JAZZ with a Outperform rating, targeting 209. Market indecision has kept the 209 target in a holding pattern.

Nov 06, 2025

ELF was rated Outperform by Joel Beatty on Nov 06, 2025, with a price objective of 125. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Oct 16, 2025

On Oct 16, 2025, Joel Beatty initiated coverage on AMLX with a Outperform rating and target of 19. The Buy call has yet to be validated as shares remain 5.01 away from the target.

Sep 30, 2025

Joel Beatty issued a Outperform recommendation for LRMR on Sep 30, 2025, price target set at 7. Investors following the Buy call captured upside momentum, with shares now at 4.595.

Aug 13, 2025

On Aug 13, 2025, EDIT was evaluated by Joel Beatty, who gave a Outperform rating and target of 6. Investors saw limited payoff as shares fell short of the 6 target.

May 19, 2025

ACAD received a Outperform rating from Joel Beatty on May 19, 2025, aiming for 31. The rating hasn’t played out as hoped, with the stock trading 6.28% below expectations.

May 07, 2025

On May 07, 2025, Joel Beatty published a Outperform outlook on PTCT, with a target of 66. Shares gained 58.22%, underscoring the accuracy of the bullish outlook toward 66.

Mar 07, 2025

Joel Beatty on Mar 07, 2025 assigned MNMD a Outperform rating, with a price target of 16. The Buy call aligned well with market performance, producing a gain of 163.98%.

Mar 03, 2025

CPRX was rated Outperform by Joel Beatty on Mar 03, 2025, with a price objective of 32. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Mar 03, 2025

On Mar 03, 2025, Joel Beatty initiated coverage on AXSM with a Outperform rating and target of 160. The stock’s climb of 22.75% since the call highlights the foresight in the rating.

Jan 07, 2025

Joel Beatty issued a Outperform recommendation for DNLI on Jan 07, 2025, price target set at 31. The target of 31 remains in play, though confirmation will depend on future moves.

Nov 25, 2024

On Nov 25, 2024, DRUG was evaluated by Joel Beatty, who gave a Outperform rating and target of 75. This case illustrates how a timely bullish rating can translate into tangible gains of 86.58%.

Aug 02, 2024

Joel Beatty rated BPMC as Outperform on Aug 02, 2024, setting a price target of 127. The call has proven timely, with shares rising 33.85% toward the price target of 127.

Jul 25, 2024

On Jul 25, 2024, ALKS was given a Outperform rating by Joel Beatty, with a target price of 38. The stock traded sideways with a -1.00% move, keeping the bullish thesis unresolved.

Jul 11, 2024

LBPH received a Outperform rating from Joel Beatty on Jul 11, 2024, aiming for 60. Momentum has favored the Buy call, with shares climbing from 59.98 to 59.98, rewarding those who trusted the recommendation.

Jan 30, 2024

Joel Beatty on Jan 30, 2024 assigned BMRN a Outperform rating, with a price target of 104. The call has struggled to gain traction, with shares losing 34.71%.